To further elucidate the role of angiogenesis in the pathogenesis of chronic myelogenous leukemia (CML) we evaluated the effects of the bcr-abl translocation on the secretion of the angiogenic factors VEGF, FGF-2, HGF, IL-8 and matrix metalloproteinases (MMPs) as well as on the angiogenic potential in vivo of bcr-abl + cells. First, we examined murine FL5.12 cells transfected with the bcr-abl constructs p185, p210 and p230 and found that the transfected cells secreted as much as four-fold more VEGF (p185 Ͼ p210 Ͼ p230) than wild-type (wt) cells, as well as MMP-9 and MMP-2. When Matrigel fragments containing these bcr-abl + cells were implanted subcutaneously in SCID or Balb-C mice they became significantly more vascularized and hemoglobinized than implants containing normal or wt cells (p185 Ͼ p210 Ͼ p230). Similarly, we found that myeloblasts expanded from bone marrow (BM) CD34
Introduction
Angiogenesis, the formation of new blood vessels from preexisting endothelium-lined vessels, has now been recognized as integral to the growth and progression of solid tumors. 1, 2 New evidence is accumulating that implicates angiogenesis in the growth and progression of hematologic malignancies, especially acute lymphoblastic leukemia 3 , acute myeloid leukemia, 4 B cell chronic lymphocytic leukemia, 5 multiple myeloma 6, 7 and myelodysplastic syndromes. 8, 9 Angiogenesis involves degradation of extracellular matrix (ECM) proteins and activation, proliferation and migration of endothelial cells in a multi-step process. Angiogenesis is mediated by a balance of various positive (eg vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), hepatocyte growth factor (HGF), interleukin-8 (IL-8), matrix metalloproteinases (MMPs)) and negative (eg platelet factor-4 (PF-4), tissue inhibi-tors of metalloproteinases (TIMPs)) angiogenic molecules released by tumor cells. In turn, these proliferating, newly formed columns of endothelial cells may stimulate tumor growth in a paracrine manner. 10, 11 We reported previously that human primary chronic myelogenous leukemic (CML) cells secrete VEGF and suggested expansion/activation of endothelium may also play a role in progression from chronic to accelerated and blastic phases of CML. 12 Recently, other investigators have found increased plasma levels of VEGF as well as other angiogenic factors such as FGF-2 and HGF and increased marrow vascularity in patients with CML. 9, 13 It has been recognized that migration of proliferating endothelial cells requires a regulated degradation of the basement membrane and surrounding ECM, which involves the production of ECM-degrading proteinases such as MMPs. 14 MMPs, a family of zinc-dependent endopeptidases that degrade all proteins in the ECM, are categorized according to their substrate specificity and domain structure into collagenases, gelatinases, stromelysins and membrane-type (MT)-MMPs. MMPs, specifically the gelatinases MMP-2 and MMP-9, play a role in angiogenesis owing to their ability to degrade components of basement membrane such as type IV collagen and fibronectin.
14 MMP activities are controlled by natural tissue inhibitors of MMPs (TIMPs). 15 MMP-2 and MMP-9 are secreted in latent form, with pro-MMP-9 being activated through cleavage by other secreted MMPs and pro-MMP-2 via the formation at the cell surface of a quaternary complex of proMMP-2, TIMP-2 and MT1-MMPs.
14 MMPs are produced by many cell types, including endothelial, epithelial and connective tissues and normal and malignant hematopoietic cells. [14] [15] [16] [17] [18] [19] [20] We previously reported that leukemic cells secrete MMP-2 in addition to MMP-9, and suggested that the former is implicated in the invasive phenotype of leukemia. 17, 18 CML is a clonal multilineage myeloproliferative disorder caused by the bcr-abl fusion oncogene. [21] [22] [23] [24] This oncogene exists in three principal forms which give rise to three distinct fusion proteins p185, p210 and p230, each of which contains the same portion of the c-abl tyrosine kinase in the COOH terminus but includes different amounts of bcr sequence at the NH 2 terminus. There is some evidence that these three bcr-abl fusion proteins are associated with distinct forms of leukemia, with p210 being found in hematopoietic cells of CML patients in the stable, chronic phase. 24 To further elucidate the role of angiogenesis in the pathogenesis of CML we examined the effects of the bcr-abl translocation on the secretion of angiogenic factors including MMPs. We also evaluated the in vivo angiogenic potential of murine bcr-abl + FL5.12 cells transfected with the bcr-abl constructs p185, p210 and p230 and of BM MNC derived from CML patients, by implanting them as Matrigel inserts into SCID or Balb-C mice.
Materials and methods

bcr-abl constructs
FL5.12 wild-type (wt) cells and cells transduced with the bcrabl constructs p185, p210 and p230 25 (a generous gift from Dr Warren Pear, Department of Pathology University of Pennsylvania, Philadelphia, PA,USA) were maintained in cultures as described for 32D cells. 26 Briefly, the parental murine interleukin-3 (IL-3)-dependent pro-B cell line FL5.12 25 was cultured in RPMI with 10% fetal calf serum, 100 U/ml penicillin (GIBCO), and 2 mmol/l L-glutamine (GIBCO) with 10% WEHI-conditioned medium as a source of IL-3. Cells were transduced by spinoculation 27 with an MSCV-based retroviral vector co-expressing bcr-abl P230, 26 P210, 28 or P185 and green fluorescence protein (GFP) through an internal ribosomal entry site (IRES). FL5.12 cells become IL-3 independent upon bcr-abl expression. Two days following retroviral infection cells were selected by withdrawing IL-3 from the culture medium for 48 to 64 h.
Human cells
BM cells were obtained from three healthy donors and six patients diagnosed with CML after receiving their consent. MNC were isolated using Ficoll-Paque density gradient (Amersham-Pharmacia, Uppsala, Sweden), washed twice with serum-free IMDM (Gibco-BRL, Burlington, ON, Canada) and employed for Matrigel implant assays. From the remaining cells BM CD34 + cells were separated by immunoaffinity selection using MiniMACS paramagnetic beads (Miltenyi Biotec, Auburn, CA, USA) as described by us previously. [29] [30] [31] The purity of isolated BM CD34
+ cells was Ͼ95% as determined by fluorescence activated cell sorter (FACS) analysis and colony-forming unit granulocyte-macrophage (CFU-GM) cells were ex vivo expanded from these cells (normal and CML derived) in a serum-free liquid system containing recombinant human (rh) IL-3 (10 ng/ml) and rh GM colony-stimulating factor (CSF) (5 ng/ml), both from R&D Systems (Minneapolis, MN, USA) as previously described. [29] [30] [31] Cultures were incubated for 10-12 days at 37°C in a fully humidified atmosphere supplemented with 5% CO 2 . Under these conditions, 100% of the CFU-GM-derived myeloid cells were glycophorin Aand ␣ IIb /␤ 3 -negative and CD33-positive. These cells were employed for ELISA assays.
Peripheral blood (PB) was obtained with their consent from six healthy donors and 16 patients diagnosed with Philadelphia-positive CML, three of whom were in the accelerated phase and 13 in the chronic phase (Table 3 ). All CML patients had t(9:22)(q34:q11) at the time of study. Six were studied at diagnosis while the rest had been undergoing treatment with hydroxyurea (five), STI 571 (three) and interferon (two). Mononuclear cells were isolated using Ficoll-Paque density gradient (Amersham-Pharmacia, Uppsala, Sweden), washed twice with serum-free IMDM (Gibco-BRL) and aliquoted into sterile Eppendorf tubes or pelleted. These cells were used for MMP and TIMP studies.
ELISA assays
The secretion of angiogenic factors was evaluated by Quantikine human immunoassays (all kits were from R&D Systems) according to the manufacturer's protocol. Murine FL5.12 cells
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(1 × 10 6 cells/ml) and human normal or CML myeloblasts (CFU-GM-derived cells) were cultured for 24 h under serumfree conditions and the conditioned media were collected and analyzed by ELISA. The sensitivities of the ELISA assays were as follows: HGF Ͼ40 pg/ml, VEGF Ͼ5 pg/ml, FGF-2 Ͼ3 pg/ml and IL-8 Ͼ1 pg/m.
MMP and TIMP assays
These assays were performed on murine FL5.12 cells, MNC isolated from the PB of CML patients and, in some cases, from BM. To evaluate the activities of MMPs and their inhibitors (TIMPs), cells were incubated in serum-free IMDM at a concentration of 2 × 10 6 cells/ml for 18-24 h at 37°C and 5% CO 2 , and conditioned media were analyzed by zymography and reverse zymography as previously described in detail by us. 16, 17, 32 Briefly, zymography was carried out using a 12% polyacrylamide gel copolymerized with 1.5 mg/ml gelatin (Sigma, St Louis, MO, USA), and clear bands at 92 kDa and 72 kDa against a Coomassie blue background indicated the presence of latent forms of MMP-9 and MMP-2, respectively. The intensity of the bands was analyzed by densitometry using a ScanJet 6200C scanner (Hewlett Packard, Palo Alto, CA, USA) and a Kodak digital science 1D Image Analysis Software (Eastman Kodak, Rochester, NY, USA). Reverse zymography was performed using 12% polyacrylamide containing 1.75 mg/ml gelatin and 160 ng/ml recombinant MMP-2 (Oncogene Research Products, Cambridge, MA, USA), and dark blue bands against a light blue background indicated TIMP activities. In some experiments MNC separated from either BM or PB of the same CML patients was also incubated for 24 h at 37°C and 5% CO 2 with or without VEGF (100 ng/ml; MJS Biolynx, Brockville, ON, Canada) and the conditioned media analyzed by zymography and reverse zymography as before.
RT-PCR analysis
To evaluate gene expression for MMPs and TIMPs in these cells total RNA was extracted as described previously. 32 The conversion of mRNA to cDNA (reverse transcription) was carried out using AMVRT (Seigaku America, Ijamsville, MD, USA). Polymerase chain reactions were done following the 'primer dropping' method. 33 Sequences for human MMP-2, MMP-9, MT1-MMP, TIMP-1 and TIMP-2 were obtained from Genbank (Los Alamos, NM) and used to design primer pairs as follows: 5' primer: MMP-2, 5ЈGGCCCTGTCACTCCTGAGAT; MMP-9, 5ЈCAACATCACCTATTGGATCC; MT1-MMP, 5ЈCCC TATGCCTACATCCGTGA; TIMP-1, 5ЈGCGGATCCAGCGCCC ACACACAGACACC; TIMP-2, 5ЈGGCGTTTTGCAATGCAGAT GTAG. 3Ј primer: MMP-2, 5ЈGGCATCCAGGTTATCGGGGA; MMP-9, 5ЈCGGGTGTAGAGTCTCTCGCT; MT1-MMP, 5ЈTC CATCCATCACTTGGTTAT; TIMP-1, 5ЈTTAAGCTTCCACTCC GGGGCAGATT; TIMP-2, 5ЈCACAGGAGCCGTCACTTCTC TTG.
Matrigel implants in SCID mice
Matrigel implants in mice were performed using murine FL5.12 cells, human K-562 cells and MNC isolated from the BM of CML patients. The angiogenesis assays were carried out by injecting Balb-C or SCID mice with 0.5 ml Matrigel (Collaborative Biomedical Products, Bedford, MA, USA) mixed on ice with ෂ2 × 10 7 leukemic cells or not (controls) as previously described. 34, 35 Matrigel was injected subcutaneously in the abdominal midline on day 0. The Matrigel implants were isolated after 1-2 weeks and photographed; the extent of vascularization was later studied by determination of hemoglobin content using the Drabkin method. 34, 35 Briefly, the Matrigel implants were harvested and all surrounding tissues dissected away. Cell pellets were homogenized at 4°C and assayed for hemoglobin content according to the manufacturer's protocol (Drabkin's reagent kit; Sigma Diagnostics). In some cases, histological slides from the Matrigel sections were prepared and angiogenesis was evaluated under a microscope.
Statistical analysis
Arithmetic means and standard deviations were calculated on a MacIntosh computer using Instat 1.14 (GraphPad, San Diego, CA, USA) software. Data were analyzed using the Student's t-test for unpaired samples. Statistical significance was defined as P Ͻ 0.05.
Results
VEGF secretion by bcr-abl-transformed murine cells
We compared the secretion of VEGF by murine FL5.12 wt to that of bcr-abl-transformed cells. FL5.12 cells transduced with p185, p210 and p230 constructs secreted ෂ4-to 1.6-fold more VEGF (p185 Ͼ p210 Ͼ p230) than wt FL5.12 cells (Table 1) .
MMP secretion by bcr-abl-transformed murine cells
We then compared the secretion of MMP-9 and MMP-2 by murine FL5.12 wt cells to those transduced with the constructs p185, p210 and p230 and found that cells transduced with these constructs secreted four-, three-and two-fold more MMP-2, respectively, than wt cells (Figure 1 ).
The angiogenic potential of bcr-abl + cells in vivo
The angiogenic potential of FL5.12 murine leukemic cells transduced with bcr-abl constructs was then assayed in vivo by examining the development of vasculature in fragments of Matrigel implanted subcutaneously into Balb-C mice. In these experiments 2 × 10 6 bcr-abl + cells (in 0.5 ml of Matrigel) were a 1 × 10 6 cells/ml were incubated in serum-free medium for 24 h as described in Materials and methods. The sensitivity of the ELISA assay was Ͼ5 pg/ml. Each experiment was performed three times. implanted subcutaneously per animal. In two independent experiments we found that, 1 week after implantation, Matrigel implants containing murine FL5.12 cells transduced with p185, p210 and p230 constructs became more vascularized and hemoglobinized than wt cells or Matrigel with no cells (Figure 2 ). Matrigel implants with murine FL5.12 cells transduced with p185 became more hemoglobinized than implants of p210-and p230-transduced cells, which was consistent with the highest secretion of MMP-2 observed for these cells as described above.
Angiogenesis in Matrigel implants was also induced by human leukemic cells. Implants with human bcr-abl + K-562 cells became significantly more vascularized than implants with no cells (Figure 3a) , and the angiogenic potential of human BM MNC CML cells derived from four patients was higher than with BM MNC from normal donors. CML cells stimulated angiogenesis in Matrigel implants up to three-fold more (Figure 3b) . Figure 4a shows a representative SCID mouse with a Matrigel implant containing CML-derived cells and Figure 4b a mouse with an implant lacking CML cells.
Figure 2
Vascularization of Matrigel implants containing FL5.12 wild-type and bcr-abl-transduced cells as evaluated by hemoglobin content in solubilized Matrigel fragments using Drabkin's colorimetric assay. Vascularization was also confirmed by histomorphological analysis of Matrigel implants. Data from three separate experiments are pooled together.
Bcr-abl
+ cells stimulate angiogenesis A Janowska-Wieczorek et al (1-4) or normal donor cells (control is the mean from three Matrigel implants) were implanted and the assay was done after 6 days. The asterisks indicate where statistical differences exist (P Ͼ 0.05) between control and CML sample.
Human bcr-abl + cells secrete angiogenic factors
Recently, we reported that VEGF is secreted by myeloblasts expanded ex vivo from CD34 + cells isolated from the BM of CML patients. 12 To further investigate the angiogenic potential of human bcr-abl + cells, we analyzed, in addition to VEGF, the secretion of IL-8, HGF and FGF-2 by CML-and normal CD34
+ cell-derived myeloblasts. Using highly sensitive ELISA we observed that although normal human myeloblasts secrete
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Figure 4
Matrigel implants containing human BM MNC derived from CML (blast crisis) patient (a) and normal donor (b) were implanted subcutaneously into SCID mice which were killed 6 days later. The fragment containing human CML cells became well vascularized (arrow).
VEGF and IL-8 at detectable levels, they do not secrete HGF and FGF-2 ( Table 2 ). In contrast, VEGF, IL-8, HGF and FGF-2 were secreted in high quantities by CML-derived cells. As shown in Table 2 , these CML cells secreted ෂ8-fold more VEGF and ෂ10-fold more IL-8 than cells derived from normal donors.
Human bcr-abl + cells secrete MMPs
Next we evaluated the secretion of MMP-9 and MMP-2 by MNC derived from the PB of 16 patients diagnosed with Philadelphia-positive CML. We found secretion of MMP-9 in all cases studied and of MMP-2 in six out of 16 including those from all three patients (Nos 14, 15, 16) in the accelerated phase of CML (Table 3) . Transcripts for MMP-9 were found in all 16 CML samples studied, and for MMP-2 in 10 (representative data are presented in Figure 5 , summarized in Table 3 ). Active MMP-2 was present in three cases. As the activation of MMP-2 requires the presence of MT1-MMP and TIMP-2, transcripts for MT1-MMP and TIMPs were also examined. MT1-MMP mRNA was expressed in eight out of 16 CML samples, all of which expressed MMP-2. Consistent with our previous reports, 17, 18 PB MNC from normal donors do not express and secrete MMP-2 (Table 3) . Interestingly, normal human myeloblasts ex vivo expanded from BM CD34 + cells also do not secrete MMP-2 as recently reported by us. 20 MT1-MMP transcripts were also not found in normal PB MNC. However, TIMP-1 and TIMP-2 were expressed and secreted in all the normal and CML samples tested with the exception of patient No. 1 in whom TIMP-1 was not found (Table 3) . We also found that incubation with VEGF of either BM or PB MNC from CML patients resulted in a 1.6 ± 0.4-fold stimulation of the secretion of MMP-9 relative to the control, as Table 2 Levels of VEGF and other angiogenic factors detected by the ELISA assay in media conditioned by human normal-(n = 3) and CML-CFU-GM-derived cells (n = 6) Cells were incubated for 24 h in serum-free medium at a concentration of 1 × 10 6 /ml. The sensitivities of the ELISA assays were as follows: HGF Ͼ40 pg/ml, VEGF Ͼ5 pg/ml, FGF2 Ͼ3 pg/ml and IL-8 Ͼ20 pg/ml. bsd, below sensitivity of detection. Table 3 . A summary of data for both gene and protein expression of MMPs and TIMPs in all the patients studied is also presented in Table 3 .
determined by densitometric analysis of zymograms (data not shown)), in seven out of 10 CML patients studied. The exceptions were the three samples in the accelerated phase of CML.
Discussion
Angiogenesis is an invasive process that requires proteolysis of the ECM allowing proliferation and migration of endothelial cells. Previously, we postulated that CML cells, which we have shown to secrete VEGF, may stimulate proliferation of BM endothelial cells. 12 In the first part of the current study we have demonstrated, using an experimental model of murine FL5.12 cells transfected with bcr-abl constructs, that such cells exhibit high secretion not only of VEGF but also of MMPs, and high angiogenic potential in vivo. In the second part of this study, we present evidence that primary cells from patients diagnosed with Philadelphia chromosome-positive CML also produce various endothelial stimulatory factors including MMPs and that they have the potential to stimulate angiogenesis in vivo.
We found that VEGF as well as MMP-9 and MMP-2 secretion is increased after transfection of murine FL5.12 cells with the bcr-abl constructs p185, p210 and p230. This indicates that, in addition to modulating cell proliferation, 23 survival, 36 adhesion 37 and DNA repair mechanisms, 38 the bcrabl proto-oncogene could also induce endogenous secretion of VEGF and MMPs. To evaluate directly the angiogenic potential of bcr-abl + cells we employed the in vivo Matrigel assay, a system already in use for studies of angiogenesis in solid tumors. 34, 35 Using this assay we found that both bcr-abl + murine FL5.12 cell lines and human bcr-abl + cells induced vascularization of Matrigel fragments implanted into SCID or Balb-C mice.
We observed that secretion of VEGF and MMPs by these cells, as well as their angiogenic potential in Matrigel implants, was highest for cells transduced by p185 and lowest for cells transduced by the p230 bcr-abl fusion protein. As it has been reported that the p185 protein exhibits higher tyrosine kinase activity than the p230 protein 39 this observation suggests that the angiogenic potential of the bcr-abl + cells may be regulated by tyrosine kinase activity. Hence, we postulate that one of the therapeutic effects of the tyrosine kinase inhibitors may be related to inhibition of the angiogenic feature of the bcr-abl + cells. We also examined human primary bcr-abl + myeloblasts expanded from BM CD34 + cells derived from patients diagnosed with Philadelphia chromosome-positive CML and found that they secrete VEGF and FGF-2 at nearly 10-fold higher levels than normal, as well as HGF and IL-8. VEGF stimulation of endothelium has also been shown to induce the production of hematopoietic growth factors such as SCF, Flt-3 ligand, G-CSF, M-CSF, GM-CSF, IL-6 and IL-7, 11 which could sustain the growth of leukemic cells in a paracrine manner. Moreover, VEGF stimulation of microvascular endothelial cells (derived from dermis) was also reported to increase MMP-2 production. 40 In this study we observed that VEGF stimulation of primary CML cells increases MMP-9, but not MMP-2, secretion in seven out of 10 CML cases studied, which is consistent with others' observations in AML. 41 MMPs are considered to play a crucial role in angiogenesis. The best evidence for this comes from the diminished angiogenesis observed in MMP-2-deficient mice 42 as well as from in vitro and in vivo studies showing significant inhibition of angiogenic responses with synthetic and endogenous MMP inhibitors. [43] [44] [45] Although the major function of MMPs in angiogenesis was thought to be that of degradation of basement membrane and connective tissue barriers allowing endothelial cells to migrate, it is now being recognized that MMPs have other functions as well. For example, MMPs could promote angiogenesis by regulating endothelial cell attachment, proliferation, migration and growth, either directly or indirectly by the release of growth factors from the ECM.
14 In this study we demonstrated constitutive expression and secretion of MMP-9 by bcr-abl + cells in all, and of MMP-2 in about half, of the CML patients studied, including all three in the accelerated phase of CML. Considering that MT1-MMP and TIMP-2 are known to be involved in the activation of pro-MMP-2 it is significant that we found expression of MT1-MMP transcripts paralleling that of MMP-2 in 50% of CML patients studied. In a study by others 46 only transcripts for TIMP-2, but not MT1-MMP, were found in BM MNC samples and pro-MMP-2 protein in 12% of CML patients. 46 Interestingly, we show here, for the first time, TIMP-1 and TIMP-2 expression and protein secretion in nearly all CML patients studied, which is consistent with our findings in AML. 17 Although synthetic and natural MMP inhibitors were shown to decrease angiogenesis in solid Leukemia tumors, we postulate that other cellular effects of TIMP-1 and TIMP-2 proteins unrelated to their inhibitory functions, such as promoting cell growth and survival, 14, 15 could influence angiogenesis in leukemias, an area that requires further study.
In summary, we provide direct evidence that cells transduced with bcr-abl constructs not only secrete angiogenic factors at levels higher than equivalent non-transduced cells but also stimulate the proliferation of endothelium. We also show that primary human bcr-abl + cells secrete various angiogenic factors including MMP-2 and MMP-9. A recent finding of increased vessel density and tortuous vessel architecture with increased branching of small BM vessels in BM from CML patients 13 further supports our conclusion that angiogenesis plays an important role in the pathogenesis of CML. Hence, we suggest that the anti-angiogenic therapies recently introduced for the treatment of solid tumors 11 be developed and applied also for the treatment of CML.
